MX2020013667A - Uso de mir-92a o mir-145 en el tratamiento del sindrome de angelman. - Google Patents
Uso de mir-92a o mir-145 en el tratamiento del sindrome de angelman.Info
- Publication number
- MX2020013667A MX2020013667A MX2020013667A MX2020013667A MX2020013667A MX 2020013667 A MX2020013667 A MX 2020013667A MX 2020013667 A MX2020013667 A MX 2020013667A MX 2020013667 A MX2020013667 A MX 2020013667A MX 2020013667 A MX2020013667 A MX 2020013667A
- Authority
- MX
- Mexico
- Prior art keywords
- mir
- treatment
- angelman syndrome
- expression
- angelman
- Prior art date
Links
- 208000009575 Angelman syndrome Diseases 0.000 title abstract 4
- 108091028684 Mir-145 Proteins 0.000 title abstract 3
- 108091034121 miR-92a stem-loop Proteins 0.000 title abstract 3
- 108091041519 miR-92a-3 stem-loop Proteins 0.000 title abstract 3
- 239000013607 AAV vector Substances 0.000 abstract 1
- 108700011259 MicroRNAs Proteins 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- -1 for example Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684774P | 2018-06-14 | 2018-06-14 | |
| PCT/US2019/037174 WO2019241624A1 (en) | 2018-06-14 | 2019-06-14 | Use of mir-92a or mir-145 in the treatment of angelman syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013667A true MX2020013667A (es) | 2021-03-02 |
Family
ID=68839583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013667A MX2020013667A (es) | 2018-06-14 | 2019-06-14 | Uso de mir-92a o mir-145 en el tratamiento del sindrome de angelman. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10704048B2 (https=) |
| EP (1) | EP3793567A4 (https=) |
| JP (1) | JP2021527087A (https=) |
| KR (1) | KR20210040358A (https=) |
| CN (1) | CN112739353A (https=) |
| AU (1) | AU2019285298A1 (https=) |
| CA (1) | CA3103267A1 (https=) |
| IL (1) | IL279391A (https=) |
| MX (1) | MX2020013667A (https=) |
| WO (1) | WO2019241624A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020002148A (es) * | 2017-08-25 | 2020-07-20 | Ovid Therapeutics Inc | Vectores adenoasociados recombinantes. |
| MX2020013667A (es) | 2018-06-14 | 2021-03-02 | Ovid Therapeutics Inc | Uso de mir-92a o mir-145 en el tratamiento del sindrome de angelman. |
| WO2020227604A1 (en) * | 2019-05-08 | 2020-11-12 | Nova Southeastern University | Regulation of nucleotide excision repair (ner) by microrna for treatment of breast cancer |
| KR20230128001A (ko) * | 2020-12-01 | 2023-09-01 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 엔젤만 증후군의 치료를 위한 조성물 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5752515A (en) | 1996-08-21 | 1998-05-19 | Brigham & Women's Hospital | Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier |
| WO2006128245A1 (en) | 2005-06-03 | 2006-12-07 | Southern Adelaide Health Service-Flinders Medical Centre | Targeting cells with altered microrna expression |
| EP1937151A4 (en) | 2005-09-19 | 2011-07-06 | Univ Columbia | Systems and methods for opening of the blood-brain barrier of a subject using ultrasound |
| CN102676516B (zh) * | 2011-03-17 | 2014-06-04 | 中国医学科学院肿瘤研究所 | microRNA 145的新用途 |
| WO2013056216A1 (en) * | 2011-10-14 | 2013-04-18 | New York University | Micrornas and methods of using same |
| AU2013262709A1 (en) * | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
| ES2809199T3 (es) | 2012-06-25 | 2021-03-03 | Ionis Pharmaceuticals Inc | Modulación de la expresión de UBE3A-ATS |
| HUE062186T2 (hu) * | 2015-05-07 | 2023-09-28 | Univ South Florida | Módosított UBE3A gén az Angelman-szindróma génterápiás megközelítésére |
| US20190298843A1 (en) * | 2015-05-11 | 2019-10-03 | Purdue Research Foundation | Ligand ionophore conjugates |
| IL256912B2 (en) * | 2015-07-17 | 2024-01-01 | Ovid Therapeutics Inc | Methods of treating developmental disorders with gaboxadol |
| MX2020013667A (es) | 2018-06-14 | 2021-03-02 | Ovid Therapeutics Inc | Uso de mir-92a o mir-145 en el tratamiento del sindrome de angelman. |
-
2019
- 2019-06-14 MX MX2020013667A patent/MX2020013667A/es unknown
- 2019-06-14 WO PCT/US2019/037174 patent/WO2019241624A1/en not_active Ceased
- 2019-06-14 US US16/441,391 patent/US10704048B2/en active Active
- 2019-06-14 JP JP2020568984A patent/JP2021527087A/ja not_active Withdrawn
- 2019-06-14 EP EP19819943.2A patent/EP3793567A4/en not_active Withdrawn
- 2019-06-14 AU AU2019285298A patent/AU2019285298A1/en not_active Abandoned
- 2019-06-14 KR KR1020217001109A patent/KR20210040358A/ko not_active Withdrawn
- 2019-06-14 CA CA3103267A patent/CA3103267A1/en active Pending
- 2019-06-14 CN CN201980040006.2A patent/CN112739353A/zh active Pending
-
2020
- 2020-07-07 US US16/922,273 patent/US11130952B2/en active Active
- 2020-12-13 IL IL279391A patent/IL279391A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11130952B2 (en) | 2021-09-28 |
| WO2019241624A1 (en) | 2019-12-19 |
| US20200332294A1 (en) | 2020-10-22 |
| US20190382761A1 (en) | 2019-12-19 |
| EP3793567A1 (en) | 2021-03-24 |
| IL279391A (en) | 2021-01-31 |
| CA3103267A1 (en) | 2019-12-19 |
| KR20210040358A (ko) | 2021-04-13 |
| US10704048B2 (en) | 2020-07-07 |
| CN112739353A (zh) | 2021-04-30 |
| JP2021527087A (ja) | 2021-10-11 |
| AU2019285298A1 (en) | 2021-01-07 |
| EP3793567A4 (en) | 2021-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017550069A1 (en) | Tau antisense oligomers and uses thereof | |
| MX2020013667A (es) | Uso de mir-92a o mir-145 en el tratamiento del sindrome de angelman. | |
| MX2022003116A (es) | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. | |
| MX2025014318A (es) | Vector de adenovirus de chimpance util para la administracion de neoantigenos | |
| SA519401379B1 (ar) | علاج فيروس مرتبط بغدة لمرض هنتنجتون | |
| BR112017004349A2 (pt) | terapia com gene de globina para o tratamento de hemoglobinopatias | |
| CA3062698A1 (en) | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof | |
| MX2016013832A (es) | Composiciones y metodos para tratar hemoglobinopatias. | |
| WO2016037071A3 (en) | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 | |
| MX388146B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
| EP4089172A3 (en) | Multiple vector system and uses thereof | |
| WO2016065349A8 (en) | Short non-coding protein regulatory rnas (sprrnas) and methods of use | |
| MY191210A (en) | Novel promoter and uses thereof | |
| MX2013014544A (es) | Vectorales de terapia genica para adrenoleucodistrofia y adrenomieloneuropatia. | |
| BR112015024605A2 (pt) | sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo | |
| EP3800255A3 (en) | Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain | |
| EP4678754A3 (en) | A modified mglur6 promoter and methods of use | |
| MX2015014423A (es) | Administración efectiva de genes grandes por vectores aav duales. | |
| SA517380883B1 (ar) | Viii مجموعة تعبير متطورة لحزم والتعبير عن عامل متغير لعلاج اضطراب توقف نزيف الدم | |
| PH12020500570A1 (en) | Alpha-synuclein antisense oligonucleotides and uses thereof | |
| CA3057899A1 (en) | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof | |
| WO2020104649A3 (en) | Novel rna compositions and methods for inhibiting angptl8 | |
| MX2018005467A (es) | Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas. | |
| AU2017248848A1 (en) | Enhanced gene delivery methods | |
| CA2986376C (en) | Poxvirus-derived promoter, and vector comprising same |